RS51636B - Derivati n-((3-okso- 2,3-dihidro-1h-izoindol-1-il) acetil) gvanidina kao inhibitori nhe-1 za lečenje infarkta i angine pektoris - Google Patents

Derivati n-((3-okso- 2,3-dihidro-1h-izoindol-1-il) acetil) gvanidina kao inhibitori nhe-1 za lečenje infarkta i angine pektoris

Info

Publication number
RS51636B
RS51636B YUP104804A RS51636B RS 51636 B RS51636 B RS 51636B YU P104804 A YUP104804 A YU P104804A RS 51636 B RS51636 B RS 51636B
Authority
RS
Serbia
Prior art keywords
dihydro
oxo
isoindol
guanidine
acetyl
Prior art date
Application number
Other languages
English (en)
Serbian (sr)
Inventor
Heinz-Werner Kleemann
Baptiste Ronan
Armin Hofmeister
Antony Bigot
Serge Mignani
Jean-Christophe Carry
Original Assignee
Sanofi-Aventis Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh. filed Critical Sanofi-Aventis Deutschland Gmbh.
Publication of RS104804A publication Critical patent/RS104804A/sr
Publication of RS51636B publication Critical patent/RS51636B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
YUP104804 2002-06-03 2003-05-20 Derivati n-((3-okso- 2,3-dihidro-1h-izoindol-1-il) acetil) gvanidina kao inhibitori nhe-1 za lečenje infarkta i angine pektoris RS51636B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0206783A FR2840302B1 (fr) 2002-06-03 2002-06-03 Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
PCT/EP2003/005279 WO2003101450A1 (en) 2002-06-03 2003-05-20 N- ((3-oxo2, 3-dihydro-1h-isoindol-1-yl) acetyl) guanidine derivatives as nhe-1 inhibitors for the treatment of infarction and angina pectoris

Publications (2)

Publication Number Publication Date
RS104804A RS104804A (sr) 2006-12-15
RS51636B true RS51636B (sr) 2011-08-31

Family

ID=29558914

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP104804 RS51636B (sr) 2002-06-03 2003-05-20 Derivati n-((3-okso- 2,3-dihidro-1h-izoindol-1-il) acetil) gvanidina kao inhibitori nhe-1 za lečenje infarkta i angine pektoris

Country Status (41)

Country Link
US (2) US7078428B2 (https=)
EP (1) EP1528923B1 (https=)
JP (1) JP4634793B2 (https=)
KR (1) KR101149771B1 (https=)
CN (1) CN1290833C (https=)
AR (1) AR039927A1 (https=)
AT (1) ATE324889T1 (https=)
AU (1) AU2003240677B2 (https=)
BR (1) BR0311556A (https=)
CA (1) CA2488373C (https=)
CY (1) CY1105115T1 (https=)
DE (1) DE60305042T2 (https=)
DK (1) DK1528923T3 (https=)
EC (1) ECSP045472A (https=)
EG (1) EG24784A (https=)
ES (1) ES2261939T3 (https=)
FR (1) FR2840302B1 (https=)
HN (1) HN2003000162A (https=)
HR (1) HRP20041151B1 (https=)
IL (1) IL165520A (https=)
JO (1) JO2357B1 (https=)
MA (1) MA27308A1 (https=)
ME (1) MEP27508A (https=)
MX (1) MXPA04011931A (https=)
MY (1) MY142502A (https=)
NO (1) NO329224B1 (https=)
NZ (1) NZ536953A (https=)
OA (1) OA12864A (https=)
PA (1) PA8574701A1 (https=)
PE (1) PE20040531A1 (https=)
PL (1) PL372188A1 (https=)
PT (1) PT1528923E (https=)
RS (1) RS51636B (https=)
RU (1) RU2318809C2 (https=)
SI (1) SI1528923T1 (https=)
TN (1) TNSN04237A1 (https=)
TW (1) TWI286545B (https=)
UA (1) UA81118C2 (https=)
UY (1) UY27835A1 (https=)
WO (1) WO2003101450A1 (https=)
ZA (1) ZA200409094B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10356717A1 (de) * 2003-12-02 2005-07-07 Aventis Pharma Deutschland Gmbh Verfahren zur Herstellung von (3-Oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-Derivaten
US7531569B2 (en) 2003-12-02 2009-05-12 Sanofi-Aventis Deutschland Gmbh Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives
KR100518184B1 (ko) * 2003-12-27 2005-10-04 한국화학연구원 퓨란카보닐구아니딘 유도체, 그의 제조방법 및 그를포함하는 약학적 조성물
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US20070161648A1 (en) * 2005-10-14 2007-07-12 Hughes Terry V Substituted dihydro-isoindolones useful in treating kinase disorders
TW200812962A (en) * 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-842之用途
SA109300358B1 (ar) 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
EP2588104B1 (en) 2010-07-01 2014-12-10 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
AR088320A1 (es) 2011-10-14 2014-05-28 Incyte Corp Derivados de isoindolinona y pirrolopiridinona como inhibidores de akt
CN103193794B (zh) * 2013-04-12 2016-04-06 中国药科大学 一种异吲哚酮并异噁唑类稠环化合物及其合成方法
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
CN106316922B (zh) * 2016-08-17 2019-02-01 华东师范大学 一种含c-3全取代氧化吲哚衍生物及其合成方法和应用
WO2018058109A1 (en) 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
CN110664803B (zh) * 2019-09-19 2023-08-29 中山大学 异吲哚酮类化合物在制备防治溶骨性疾病药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
DK0612723T3 (da) * 1993-02-20 1998-03-30 Hoechst Ag Substituerede benzoylguanidiner, fremgangsmåde til fremstilling, deres anvendelse som lægemiddel, som inhibitor af den cellulære Na+/H+-udbytning eller som diagnostikum samt lægemiddel med indhold deraf
FR2735166B1 (fr) * 1995-06-08 1997-08-29 Aerospatiale Procede de fabrication d'un panneau ou analogue a proprietes structurale et acoustique et panneau ainsi obtenu
DE19737224A1 (de) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
DE19738604A1 (de) * 1997-09-04 1999-03-11 Hoechst Marion Roussel De Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verminderung der Giftigkeit cardiotoxischer Stoffe
PT1056729E (pt) * 1998-02-27 2005-04-29 Pfizer Prod Inc Derivados de n-[ciclo di- ou tri-aza di-insaturado de cinco membros substituido) carbonil] guanidina para o tratamento de isquemia
DE19859727A1 (de) * 1998-12-23 2000-06-29 Aventis Pharma Gmbh Die Verwendung von Hemmern des Natrium-Wasserstoff-Austauschers zur Herstellung eines Medikaments zur Verhinderung von altersbedingten Organ-Dysfunktionen, altersbedingten Erkrankungen zur Lebensverlängerung
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
EP1276737A1 (en) * 2000-04-28 2003-01-22 Pfizer Products Inc. Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)
DE10046993A1 (de) * 2000-09-22 2002-04-11 Aventis Pharma Gmbh Substituierte Zimtsäureguanidide, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltendes Medikament
ATE348097T1 (de) * 2001-04-09 2007-01-15 Chiron Corp Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten

Also Published As

Publication number Publication date
HRP20041151B1 (hr) 2013-06-30
JO2357B1 (en) 2006-12-12
HRP20041151A2 (en) 2005-06-30
US20040048916A1 (en) 2004-03-11
TW200404780A (en) 2004-04-01
US7589117B2 (en) 2009-09-15
AU2003240677A1 (en) 2003-12-19
EP1528923B1 (en) 2006-05-03
AR039927A1 (es) 2005-03-09
MEP27508A (en) 2010-06-10
ES2261939T3 (es) 2006-11-16
US20060148880A1 (en) 2006-07-06
TNSN04237A1 (en) 2007-03-12
ATE324889T1 (de) 2006-06-15
CN1658869A (zh) 2005-08-24
EP1528923A1 (en) 2005-05-11
SI1528923T1 (sl) 2006-08-31
RU2004138789A (ru) 2005-06-27
CA2488373A1 (en) 2003-12-11
BR0311556A (pt) 2005-04-12
JP2005533034A (ja) 2005-11-04
CA2488373C (en) 2012-07-17
NO20045660L (no) 2004-12-27
RS104804A (sr) 2006-12-15
RU2318809C2 (ru) 2008-03-10
NO329224B1 (no) 2010-09-20
HK1076383A1 (en) 2006-01-20
OA12864A (en) 2006-09-15
ZA200409094B (en) 2005-08-31
PA8574701A1 (es) 2004-05-07
HN2003000162A (es) 2004-05-05
IL165520A (en) 2009-12-24
PE20040531A1 (es) 2004-09-27
WO2003101450A1 (en) 2003-12-11
MY142502A (en) 2010-11-30
FR2840302B1 (fr) 2004-07-16
CY1105115T1 (el) 2010-03-03
KR20050010855A (ko) 2005-01-28
PT1528923E (pt) 2006-08-31
FR2840302A1 (fr) 2003-12-05
KR101149771B1 (ko) 2012-06-08
ECSP045472A (es) 2005-01-28
UY27835A1 (es) 2003-12-31
EG24784A (en) 2010-09-01
DK1528923T3 (da) 2006-09-04
US7078428B2 (en) 2006-07-18
CN1290833C (zh) 2006-12-20
AU2003240677B2 (en) 2008-07-17
JP4634793B2 (ja) 2011-02-16
UA81118C2 (en) 2007-12-10
DE60305042T2 (de) 2007-05-24
MA27308A1 (fr) 2005-05-02
MXPA04011931A (es) 2005-03-31
DE60305042D1 (de) 2006-06-08
NZ536953A (en) 2007-10-26
PL372188A1 (en) 2005-07-11
IL165520A0 (en) 2006-01-15
TWI286545B (en) 2007-09-11

Similar Documents

Publication Publication Date Title
RS51636B (sr) Derivati n-((3-okso- 2,3-dihidro-1h-izoindol-1-il) acetil) gvanidina kao inhibitori nhe-1 za lečenje infarkta i angine pektoris
US8283374B2 (en) Process for preparing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives
AU2003250873A1 (en) 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them
US7531663B2 (en) 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, preparation process, their use as medicaments, and pharmaceutical compositions comprising them
AU2004295056B2 (en) Method for producing (3-oxo-2,3-dihydro-1H-isoindol-1-yl) acetylguanidine derivatives
ES2330524T3 (es) Deribados heterociclicos de 3-(guanidinocarbonilo), procedimiento de preperacion y compuestos intermedios de este procedimiento, su uso como medicamentos y composiciones farmaceuticas que los uncluyen.
US7230007B2 (en) Derivatives of 3-(Guanidinocarbonyl) heterocycle, methods of preparation and intermediates thereof, their use as medicaments, and pharmaceutical compositions therefrom
MXPA06005556A (en) Method for producing (3-oxo-2,3-dihydro-1h-isoindol-1-yl) acetylguanidine derivatives